CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
iRECIST: how to do it | Cancer Imaging | Full Text
iRECIST: how to do it | Cancer Imaging | Full Text
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST | Journal of Clinical Oncology
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
i RECIST A guideline for data management and
i RECIST A guideline for data management and
The Radiology Assistant : RECIST 1.1 - and more
Kaplan-Meier curves of OS and PFS based on iRECIST to compare outcomes... | Download Scientific Diagram
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
Assessing Immunotherapy Response and Progression
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
i RECIST A guideline for data management and
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Rationale Grows for the Immune-Related Response Criteria
iRECIST Overview
